Mark Lowdell | Director Of Cellular Therapy
Royal Free London NHS Foundation Trust

Mark Lowdell, Director Of Cellular Therapy, Royal Free London NHS Foundation Trust

Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital London. He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials and is the current Vice President (Europe & Middle East) of the International Society for Cell & GeneTherapy.
He has over 20 years’ experience in adoptive immunotherapy of cancer and has focussed on the role of the innate immune responses; especially the role of natural killer (NK) cells.
He has focussed particularly on translational research and established the first academic GMP facility in the UK for the production of human cells as medicines in 2003. This GMP facility now produces somatic cell medicines, gene therapies and tissue engineered products. The first cellular medicine manufactured in this facility was Professor Lowdell’s own adoptive NK cell therapy product, Tumour-primed NK cells, and, during the UK clinical trial he led the technology transfer of this into three commercial CMOs in the US and was the chief scientific officer for the US clinical trial. 
His newly refurbished ATMP GMP suite at RFH/UCL consists of 12 state-of-the-art manufacturing labs and over 20 staff supporting multiple academic and commercial trials of somatic cell and tissue engineered therapies whilst continuing his development of NK-based immunotherapies. Most recently he has founded InmuneBio Inc with Dr RJ Tesi and David Moss to develop an “off-the-shelf” iteration of the tumour-primed NK concept and the first clinical trials will open in the UK in Q4 2018.
Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. Recently he was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA including Autolus Ltd, Achilles Therapeutics Ltd, Cell Medica Ltd, InmuneBio Inc, Novamune Ltd and NWBio Therapeutics.

Appearances:



15th May Pre-Conference Workshops and Summits Day @ 13:00

The EBMR (electronic batch manufacturing record)– product quality in a black box

· Ensuring product delivery, quality control, traceability. · How can we reduce manufacturing man hours and increase efficiency using software?· Focus group to develop software to trace product back to patient

Conference Day 1: Thursday 16th May 2019 @ 17:45

BIOPROCESSING CLOSING PLENARY: Bioprocessing Panel discussion: How to manage cell and gene therapy delivery from ‘end to end’ 

  • Sample collection, handling and logistics 
  • Regulation 
  • Product distribution 
  • Cryo-shipping strategies 
  • Manufacturing automation and cell therapy 
  • Reimbursement and integrated care 

Conference Day 1: Thursday 16th May 2019 @ 17:45

Panel discussion: How to manage cell and gene therapy delivery from ‘end to end’

  • Sample collection, handling and logistics 
  • Regulation 
  • Product distribution 
  • Cryo-shipping strategies 
  • Manufacturing automation and cell therapy 
  • Reimbursement and integrated care 
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com